Hydrazide containing nuclear transport modulators and uses thereof
View Patent ↗The invention generally relates to nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to a compound represented by structural formula I: or a pharmaceutically acceptable salt thereof, wherein the values and alternative values for the variables are as defined and described herein. The invention also includes the synthesis and use of a compound of structural formula I, or a pharmaceutically acceptable salt or composition thereof, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity.
1. A method for treating multiple myeloma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula I-3:
or a pharmaceutically acceptable salt thereof and an additional therapeutic agent selected from bortezomib, dexamethasone or a combination thereof.
2. The method of claim 1 , wherein the additional therapeutic agent is bortezomib.
3. The method of claim 1 , wherein the additional therapeutic agent is dexamethasone.
4. The method of claim 1 , wherein the additional therapeutic agent is a combination of bortezomib and dexamethasone.
5. The method of claim 1 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms.
6. The method of claim 2 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms.
7. The method of claim 3 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms.
8. The method of claim 4 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in separate dosage forms.
9. The method of claim 1 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered at the same time.
10. The method of claim 2 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered in at the same time.
11. The method of claim 3 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered at the same time.
12. The method of claim 4 , wherein the compound of structural formula I-3 and the additional therapeutic agent are administered at the same time.
13. The method of any one of claims 1 - 12 , wherein the compound of structural formula I-3 is orally administered.